Hookipa Pharma (HOOK) Expected to Announce Earnings on Thursday

Hookipa Pharma (NASDAQ:HOOK) will likely be issuing its quarterly earnings data before the market opens on Thursday, March 20th. Analysts expect the company to announce earnings of ($0.69) per share and revenue of $6.50 million for the quarter.

Hookipa Pharma Price Performance

NASDAQ HOOK opened at $1.25 on Thursday. Hookipa Pharma has a 1 year low of $1.11 and a 1 year high of $10.50. The company has a market capitalization of $15.07 million, a PE ratio of -0.34 and a beta of 0.71. The company has a fifty day moving average of $1.78 and a 200 day moving average of $2.94.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on HOOK shares. Royal Bank of Canada cut Hookipa Pharma from an “outperform” rating to a “sector perform” rating and decreased their price objective for the company from $48.00 to $2.00 in a report on Friday, December 20th. JMP Securities decreased their price target on Hookipa Pharma from $24.00 to $7.00 and set a “market outperform” rating for the company in a report on Thursday, November 21st. Finally, HC Wainwright reaffirmed a “neutral” rating on shares of Hookipa Pharma in a research note on Friday, January 10th.

About Hookipa Pharma

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.